Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

MRx0518 and Pembrolizumab Combination Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03637803
Recruitment Status : Recruiting
First Posted : August 20, 2018
Last Update Posted : May 8, 2019
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
4D pharma plc

Brief Summary:

This is a single center, open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma).

Subjects will be treated with IV pembrolizumab every 3 weeks and 1 capsule twice daily of MRx0518. Treatment will continue as long as clinically relevant, until disease progression, unacceptable AEs or withdrawal of consent up to a maximum of 35 cycles (approx. 2 years).


Condition or disease Intervention/treatment Phase
Oncology Solid Tumor Non Small Cell Lung Cancer Renal Cell Carcinoma Melanoma Bladder Cancer Drug: MRx0518 Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA] Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 132 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Open Label, Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1 Inhibitors
Actual Study Start Date : January 10, 2019
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : March 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MRx0518 with pembrolizumab
Subjects will receive IV infusion of pembrolizumab once every 3 weeks until disease progression, unacceptable AEs or withdrawal of consent up to a maximum of 35 cycles (approx. 2 years). Starting on the day of first pembrolizumab dose, subjects will take one capsule of MR0518 twice daily until the end of the treatment period.
Drug: MRx0518
MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.

Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Pembrolizumab is a potent humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD1) receptor , thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). The study dosing regimen is 200mg (two 4ml vials of 25mg/ml solution) for IV infusion once every three weeks.
Other Names:
  • MK3475
  • Pembrolizumab
  • Keytruda




Primary Outcome Measures :
  1. Part A: To assess the safety and tolerability of MRx0518 in combination with pembrolizumab through the collection of adverse events [ Time Frame: Baseline to treatment discontinuation up to a maximum of 35 treatment cycles (one cycle = 21 days) ]
    Adverse events will be assessed as per CTCAE v4

  2. Part B: To assess safety and tolerability of MRx0518 in combination with pembrolizumab through the collection of adverse events [ Time Frame: Baseline to treatment discontinuation up to a maximum of 35 treatment cycles (one cycle = 21 days) ]
    Adverse events will be assessed as per CTCAE v4

  3. Part B: To assess the clinical benefit of MRx0518 in combination with pembrolizumab [ Time Frame: Baseline to treatment discontinuation up to a maximum of 35 treatment cycles (one cycle = 21 days) ]
    To determine preliminary evidence of anti-tumor activity


Secondary Outcome Measures :
  1. Antitumour effect [ Time Frame: Baseline and every 3 weeks until treatment discontinuation up to a maximum of 35 treatment cycles (one cycle = 21 days) ]
    Antitumour effect is assessed through tumour imaging and measurement of lesions per RECIST and iRECIST (ORR, DOR, DCR, PFS)


Other Outcome Measures:
  1. Biomarkers of treatment effect - blood [ Time Frame: Day 1 of Cycle 1 and Cycle 2 and time of treatment discontinuation up to a maximum of 35 treatment cycles (one cycle = 21 days) ]
    Blood samples will be analysed for changes in immune status and biomarkers of treatment effect

  2. Biomarkers of treatment effect - tumour [ Time Frame: Baseline, Day 1 of Cycle 4 and time of treatment discontinuation up to a maximum of 35 treatment cycles (one cycle = 21 days) ]
    Tissue biopsies will be taken to analyse for tumour biomarkers

  3. Microbiota and metabolome [ Time Frame: Day 1 of Cycle 1 and Cycle 2, time of treatment discontinuation up to a maximum of 35 treatment cycles (one cycle = 21 days), and 30 Day follow up ]
    Faecal and urine samples will be collected and analysed for microbiota and metabolomics using the MicroDx platform

  4. Overall survival [ Time Frame: From start of treatment until death due to any cause up to a maximum of 35 treatment cycles (one cycle = 21 days) ]
    Survival of the subjects will be recorded



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Willing and able to provide written informed consent/assent for the trial.
  • ≥18 years of age on day of signing informed consent.
  • Histological or cytological evidence of advanced and/or metastatic or recurrent NSCLC, renal cell carcinoma, bladder cancer or melanoma.
  • At least one measurable lesion per RECIST v 1.1 criteria.
  • Failure to respond or intolerance to standard therapy or for whom no appropriate therapies are known to provide clinical benefit (per the judgement of the Investigator).
  • Subjects must have progressed on treatment with a PD-1 inhibitor administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies. PD-1 inhibitor treatment progression is defined by meeting all of the following criteria:

    1. Has received at least 2 doses of a PD-1 inhibitor.
    2. Has demonstrated disease progression after PD-1 therapy as defined by RECIST v1.1, iRECIST or irRECIST. The initial evidence of disease progression (PD) is to be confirmed by a second assessment no less than four weeks from the date of the first documented PD, in the absence of rapid clinical progression.
    3. Progressive disease has been documented within 12 weeks from the last dose of a PD-1 inhibitor.
  • Have adequate organ function
  • Be willing to provide archival tissue
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Female subjects of childbearing potential should have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for ≥2 years.
  • Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication
  • Male subjects with female partners of childbearing potential should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.

Exclusion Criteria:

  • Subjects who failed to show any response to initial treatment with PD-1 inhibitor (i.e. no Response or no Stable Disease).
  • Has active brain metastases or leptomeningeal disease. Subjects with asymptomatic CNS metastases which have been stable (defined as without evidence of progression by MRI for at least 28 days prior to initiation of therapy and any neurologic symptoms have returned to baseline) following treatment with surgery or radiation therapy are allowed.
  • Prior solid organ or hematologic transplant.
  • Treatment-related immune-mediated (or immune related) AEs from immune-modulatory agents (including but not limited to anti-PD1/PD-L1 agents, anti-CTLA4 monoclonal antibodies) that caused permanent discontinuation of the agent, or that were grade 3 or 4 in severity.
  • Subjects treated with chemotherapy, immunotherapy, biologic therapy, or other investigational agent within <5 times the half-life of the agent or <21 days (whichever is shorter) of starting study drug. Continuation of hormone replacement therapy is permitted. Stable regimens of hormonal therapy i.e. for prostate cancer (e.g. leuprolide, a GnRH agonist), ovarian, or breast cancer are not exclusionary.
  • Subjects treated with tyrosine kinase inhibitor therapy or completed palliative radiotherapy <14 days from initiation of therapy.
  • Comorbidity requiring corticosteroid therapy (>10mg prednisone/day or equivalent) within 7 days of starting experimental therapy. Physiologic replacement doses are allowed if they are ≤10mg of prednisone/day or equivalent, as long as they are not being administered for immunosuppressive intent. Inhaled or topical steroids are permitted, provided that they are not for treatment of an autoimmune disorder.
  • Significant cardiac dysfunction

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03637803


Contacts
Layout table for location contacts
Contact: Clinical Operations +441138950130 clinicaltrials@4dpharmaplc.com

Locations
Layout table for location information
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Shubham Pant, MD         
Sponsors and Collaborators
4D pharma plc
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Principal Investigator: Shubham Pant, MD M.D. Anderson Cancer Center

Layout table for additonal information
Responsible Party: 4D pharma plc
ClinicalTrials.gov Identifier: NCT03637803     History of Changes
Other Study ID Numbers: MRx0518-I-002
Keynote MK3475-823 ( Other Identifier: Merck )
First Posted: August 20, 2018    Key Record Dates
Last Update Posted: May 8, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by 4D pharma plc:
MK-3475
pembrolizumab
MRx0518
PD-1 Inhibitor
Oncology
Live Biotherapeutic Product

Additional relevant MeSH terms:
Layout table for MeSH terms
Pembrolizumab
Carcinoma, Non-Small-Cell Lung
Urinary Bladder Neoplasms
Carcinoma, Renal Cell
Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Urologic Neoplasms
Urogenital Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Kidney Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents